2015
DOI: 10.1111/ijcp.12617
|View full text |Cite
|
Sign up to set email alerts
|

Response to clarifying the costs of conflicts of interest

Abstract: Linked Comment: Citrome . 2015; 69: 267–8. Linked Comment: Clark . 2015; 69: 270–2. Linked Comment: Mayes . 2015; 69: 384–5.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
3
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 5 publications
(2 reference statements)
0
3
0
Order By: Relevance
“…Recent correspondence informs us that COI remains a 'hot button' issue (5,6). As Mayes et al point out, 'Over the past two decades, a deep suspicion has emerged in the healthcare community about the influence of private industry-particularly the pharmaceutical industry-over doctors, researchers, regulators and policymakers' (5).…”
mentioning
confidence: 99%
“…Recent correspondence informs us that COI remains a 'hot button' issue (5,6). As Mayes et al point out, 'Over the past two decades, a deep suspicion has emerged in the healthcare community about the influence of private industry-particularly the pharmaceutical industry-over doctors, researchers, regulators and policymakers' (5).…”
mentioning
confidence: 99%
“…Much in fact turned on the discloser's perceived motives. Focus on the presumed motives of authors, however, detracts from an unbiased evaluation of the content of a publication, and is the epitome of an ad hominem approach to science (Acquavella 1997;Rothman 1993;Stossel 2007;Stossel, Barton, and Stell 2015). Avoiding this focus need not gainsay the profound influence authors' interests can have on the content of their publications; it is only to recognize that such content can be evaluated independently of those interests.…”
Section: Disclosed Conflicts Of Interest Don't Contain Enough Informa...mentioning
confidence: 99%
“…Partly this has been due to the systematic distortion of the evidence base and other abuses committed by the pharmaceutical industry (Angell 2005;Every-Palmer and Howick 2014). Recently, the rhetoric surrounding COI reporting has increased to a boiling point, marked by heavy debate and diametrically opposed positions over what COIs are, what effects they are likely to engender, and how they should be managed-if at all (Acquavella and Ramlow 1997;Cappola and FitzGerald 2015;Elliot 2014;Fineberg 2017;Fontanarosa and Bauchner 2017;Johnson and Horn 2010;Lee [44.224.250.200] Project MUSE (2024-06-03 15:52 GMT) KENNEDY INSTITUTE OF ETHICS JOURNAL • MARCH 2022 [ 104 ] 2008; Loewenstein, Sah, and Cain 2012;Mayes, Lipworth, and Kerridge 2015;McKinney and Pierce 2017;Mintzes and Grundy 2018;Psaty 2009;Resnik and Elliot 2013;Rosenbaum 2015aRosenbaum , 2015bRosenbaum , 2015cRothman 1993;Steinbrook, Kassierer, and Angell 2015;Stossel 2008;Stossel, Barton, and Stell 2015;Tarone 2018;Wiersma et al 2018a, b). More and more journals require disclosure, and recommendations have been made that religious (Smith and Blazeby 2018), dietary (Ioannidis and Trepanowski 2018), and other non-financial disclosures be added to the list of financial disclosures (Wiersma et al 2018a, b).…”
mentioning
confidence: 99%